[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as in...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 15; no. 10; p. 1292
Main Authors Hennrich, Ute, Eder, Matthias
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 20.10.2022
MDPI
Subjects
[177Lu]Lu-PSMA-617
Antigens
Cancer therapies
Chemotherapy
Energy
FDA approval
Kidneys
Medical research
Patients
Pharmacokinetics
PluvictoTM
Prostate cancer
PSMA
radioligand therapy (RLT)
Retention
Review
theranostics
Tomography
Tumors
United Kingdom > UK
United States > US
Basel Switzerland
Switzerland
Germany
Online AccessGet full text

Cover

More Information
Summary:In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [177Lu]Lu-PSMA-617 was demonstrated.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15101292